Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05485753
Other study ID # GNC-038-103
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date February 10, 2023
Est. completion date May 2025

Study information

Verified date January 2024
Source Sichuan Baili Pharmaceutical Co., Ltd.
Contact Hai Zhu
Phone +86-13980051002
Email zhuhai@baili-pharm.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. The subject can understand the informed consent, participate in and sign the informed consent voluntarily; - 2. No gender limitation; - 3. Age: =18; - 4. Expected survival time =3 months; - 5. Patients with primary CNS lymphoma (PCNSL) and secondary CNS lymphoma (SCNSL) confirmed by histology or cytology; - 6. A. Patients with recurrent/refractory primary central nervous system lymphoma (PCNSL) and recurrent/refractory secondary central nervous system lymphoma (SCNSL) may be associated with ocular lymphoma;B. Patients with relapsed or refractory primary CNS lymphoma (PCNSL) and relapsed or refractory secondary CNS lymphoma (SCNSL) who were not eligible or intolerant to other therapies were determined by the investigator;Recurrence and refractory are defined as follows: Recurrence refers to the emergence of new lesions after adequate treatment to complete response (CR).Refractory refers to a patient who has experienced at least first-line treatment without disease remission, e.g. induction chemotherapy with methotrexate without CR. - 7. KPS score =60; - 8. Adverse reactions of previous antitumor therapy returned to CTCAE 5.0 grade =1 (except for the indicators that the researchers considered to be related to the disease, such as anemia, and toxicities that the researchers determined to be without safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.); - 9. Before the first administration, the organ function level should meet the following requirements: Bone marrow function: In the absence of blood transfusion, G-CSF (long-acting white needle within 2 weeks) and medication correction within 7 days prior to screening: Absolute neutrophil count (ANC) =15×10^9/L (subjects with bone marrow infiltration should be =0.5×10^9/L);Hemoglobin =90 g/L;Platelet count =90×10^9/L; Liver function: Total bilirubin =1.5 ULN (Gilbert's syndrome =3 ULN), transaminase (AST/ALT) =2.5 ULN (=5.0 ULN for subjects with tumor invasive changes in the liver) without correction with hepatoprotective drugs within 7 days prior to screening; Renal function: Creatinine (Cr) =1.5 ULN and creatinine clearance (Ccr) =50 mL /min according to the Cockcroft and Gault formula; Routine urine / 24-hour urine protein quantification: qualitative urine protein =1+ (if qualitative urine protein =2+, 24-hour urine protein < 1g can be included); Cardiac function: left ventricular ejection fraction =50%; Coagulation function: fibrinogen =1.5g/L; Activated partial thrombin time (APTT) =1.5 ULN; Prothrombin time (PT) =1.5 ULN. - 10. Fertile female subjects or male subjects with fertile partners must use highly effective contraception beginning 7 days before the first dose and up to 12 weeks after the last dose. Fertile female subjects must have a negative serum/urine pregnancy test within 7 days prior to initial dosing; - 11. The subject is able and willing to follow the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol. Exclusion Criteria: - 1. Lung disease defined as grade =3 according to NCI-CTCAE V5.0; Patients with current interstitial lung disease (ILD) (except those who have recovered from previous interstitial pneumonia); - 2. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.; - 3. Active tuberculosis; - 4. Brain stem tumor infiltration or only eye lesions; - 5. Patients with active autoimmune diseases, such as: Systemic lupus erythematosus, systemic treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and hashimoto's thyroiditis, etc., with the exception of type I diabetes, only replacement therapy can control the hypothyroidism, no systemic treatment of skin disease (e.g., vitiligo, psoriasis), B cells caused by autoimmune disease; - 6. Non-melanoma skin cancer in situ, superficial bladder cancer, cervical cancer in situ, gastrointestinal intramucosal cancer, breast cancer, localized prostate cancer and other cancers that have been cured and have not recurred within 5 years prior to the first administration are excluded; - 7. HBsAg positive or HBcAb positive, and HBV-DNA test = the upper limit of normal; HCV antibody positive and HCV-RNA= the upper limit of normal value; HIV antibody positive; - 8. Poorly controlled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg); - 9. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: Severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias and degree ? ATrioventricular block requiring clinical intervention; Longer QT interval at rest (QTc > 450 msec for men or 470 msec for women); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other grade 3 or higher cardiovascular and cerebrovascular events occurred within 6 months prior to first administration; Heart failure with the New York Heart Association (NYHA) Heart function rating =II; 10. Patients with a history of allergy to recombinant humanized antibodies or to any excipient ingredient of GNC-038; - 11. Pregnant or breastfeeding women; - 12. Patients who cannot tolerate MRI examination; - 13. Patients who underwent major surgery within 28 days prior to administration of the drug in this study, or who planned to undergo major surgery during the study period (except for puncture or biopsy surgery); - 14. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLO-HSCT); - 15. Autologous hematopoietic stem cell transplantation (AUTO-HSCT) within 12 weeks prior to initiation of GNC-038 therapy; - 16. Immunosuppressants are being used, including but not limited to: Cyclosporine, tacrolimus, etc. within 2 weeks prior to gnC-038 treatment; Gnc-038 received a high dose of glucocorticoid for 2 weeks prior to treatment (longer than 14 days, a steady dose of dexamethasone >5mg per day or equivalent dose of other glucocorticoids); - 17. Received radiotherapy within 4 weeks prior to initiation of GNC-038 treatment; - 18. Received anti-CD20 or anti-CD79B treatment within 4 weeks prior to initiation of GNC-038 and still responded; - 19. Received chemotherapy and small molecule targeted therapy within 2 weeks prior to treatment; - 20. Received CAR-T therapy within 12 weeks prior to initiation of GNC-038; - 21. Participated in any other clinical trials within 4 weeks prior to administration of this trial; - 22. Past or present central nervous system disease, including, but not limited to, stroke (imaging) - 23. Medical examination indicated "lacunar cerebral infarction" except those requiring no treatment), severe brain injury, Senile dementia, Parkinson's disease, organic brain syndrome, psychosis; - 24. Other conditions that the investigator considers inappropriate for participation in this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GNC-038
Administration by intravenous infusion

Locations

Country Name City State
China Beijing GoBroad Boren Hospital Beijing Beijing
China Beijing Tiantan Hospital, Capital Medical University Beijing Beijing
China Guangdong Provincial People's Hospital Guangzhou Guangdong
China The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan

Sponsors (3)

Lead Sponsor Collaborator
Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., SystImmune Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) The incidence and severity of adverse events during treatment were graded according to the National Cancer Institute Standard for Common Terminology for Adverse Events (NCI-CTCAE, v5.0). Up to 17 days after the first dose
Primary Maximum tolerated dose (MTD) or maximum administrated dose (MAD) In the dose increment stage, the highest dose whose estimated DLT rate is closest to the target DLT rate but does not exceed the upper bound of the equivalent interval of DLT rate is selected as MTD. Up to 17 days after the first dose
Primary Treatment-Emergent Adverse Event (TEAE) TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of GNC-038. The type, frequency and severity of TEAE will be evaluated during the treatment of GNC-038. Up to approximately 36 months
Primary The recommended dose for phase II clinical study(RP2D) The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of GNC-038. Up to 17 days after the first dose
Secondary ORR (Objective Response Rate ) ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1. Up to approximately 36 months
Secondary PFS (Progression-free Survival) The PFS is defined as the time from the participant's first dose of GNC-038 to the first date of either disease progression or death, whichever occurs first. Up to approximately 36 months
Secondary DCR (Disease Control Rate) Number of patients showing Complete Response (CR, disappearance of all target lesions) or Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response. Up to approximately 36 months
Secondary DOR (Duration of Response) The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first. Up to approximately 36 months
Secondary CR (Complete Response) Disappearance of all target lesions. Up to approximately 36 months
Secondary Adverse Events of special interest (AESI) AESI is an event of scientific and medical interest specific to the sponsor's product or research project. Up to approximately 36 months
Secondary Peak Plasma Concentration(Cmax) Maximum serum concentration (Cmax) of GNC-038 will be investigated. Up to 17 days after the first dose
Secondary Incidence and titer of ADA (Anti-drug antibody) Frequency and titer of anti-GNC-038 antibody (ADA) will be evaluated. :Up to approximately 36 months
Secondary Incidence and titer of Nab Incidence and titer of Nab of GNC-038 will be evaluated. Up to approximately 36months
Secondary Time to reach maximum concentration (Tmax) Time to maximum serum concentration (Tmax) of GNC-038 will be investigated. Up to 17 days after the first dose
Secondary AUC0-inf Area under the plasma concentration-time curve from time 0 extrapolated to infinite (AUC0-inf). Up to 17 days after the first dose
Secondary AUC0-t Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration (AUC0-t). Up to 14 days after the first dose of GNC-038
Secondary Plasma clearance (CL) To study the serum clearance rate of GNC-038 per unit time. Up to 17 days after the first dose
Secondary Elimination half life (T1/2) Blood concentration - Area under time line. Up to 17 days after the first dose
See also
  Status Clinical Trial Phase
Recruiting NCT04083066 - Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma Phase 4
Active, not recruiting NCT02313389 - Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Phase 3
Recruiting NCT02836158 - Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Phase 2/Phase 3
Recruiting NCT02657785 - Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Phase 2/Phase 3
Recruiting NCT06445257 - A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL N/A
Recruiting NCT05135858 - Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma Phase 1
Completed NCT01421524 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma Phase 1
Active, not recruiting NCT00863460 - Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients Phase 2
Active, not recruiting NCT05036577 - A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL Phase 1
Recruiting NCT04514393 - Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Phase 2
Not yet recruiting NCT04066920 - IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL Phase 2
Recruiting NCT03733327 - BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT Phase 2/Phase 3
Recruiting NCT00455286 - a Phase II Study in Primary Central Nervous System Lymphoma Phase 2
Completed NCT02301364 - Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Phase 2
Completed NCT00112593 - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer N/A
Completed NCT02669511 - PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT04457869 - A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) Phase 2
Recruiting NCT02655744 - Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
Recruiting NCT02399189 - MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Phase 2
Recruiting NCT04831658 - A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma Phase 1/Phase 2